Keyword: Boehringer Ingelheim
Boehringer Ingelheim has recruited label design and management specialist NiceLabel to develop a global standardized labeling process.
In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.
Thursday, November 14, 2019
Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.
Eli Lilly and Boehringer Ingelheim failed to persuade an FDA expert panel that their SGLT2 med, Jardiance, could be repurposed for Type 1 diabetes.
Lilly and BI have taken the leading position with Jardiance, and now the partners are changing their 2011 alliance agreement to focus on the drug.
ICER concluded that Novo Nordisk's diabetes pill Rybelsus will be less cost-effective than Jardiance as an add-on therapy in type 2 diabetes.
COPD patients are frustrated with their inhaling devices. But doctors don't necessarily know that. In this award-winning campaign in the professional category, Boehringer Ingelheim and FCB Health got doctors to look beyond the plastic and buttons to see that the patients using the devices are "The Real Inhalers."
Interstitial lung disease has more than 200 possible causes, some unusual and obscure, but Boehringer and FCB Health used images to connect the dots.
Chris Marsh, Senior Vice President of Market Access, Boehringer Ingelheim
GlaxoSmithKline, Pfizer, Sanofi and Boehringer Ingelheim are facing lawsuit claims that they failed to test for possible carcinogens in Zantac.